Product Code: 138733-08-22
Industry Outlook
Alpha thalassemia treatment market accounted for a market value of US$ 643.4 Mn in 2021 and projected to grow at a CAGR of 7.1% during the forecast period from 2022 to 2030. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes. Alpha thalassemia usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region. The key factors responsible for growth of alpha thalassemia treatment market are the rising awareness associated with thalassemia in medical practitioners & public, and support provided by government & non-government organizations to manage and treat thalassemia.
Deferasirox being the only approved drug for alpha thalassemia treatment will dominate the market throughout the forecast period
In 2021, deferasirox will dominate the market throughout the forecast period as it is the only approved drug therapy by USFDA for alpha thalassemia. According to market experts, deferasirox possess efficient oral bioavailability and a long half-life appropriate for once-daily dosing. Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent style. It is use widely across the world for alpha thalassemia treatment because its once-per-day oral dosage. However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon but there are a few drawbacks observed in the Phase IIa that might have some effect on its approval. If it gets approved it will be observed as the fastest growing drug in this market.
Increasing awareness related to the treatment & management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period
The Asia Pacific will grow gradually throughout the forecast period from 2020 to 2030, the key factors responsible for growth of alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment & management and increasing support provided by governmental & non-governmental organizations to develop awareness in public. According to market experts, alpha-thalassemia is specifically common among Southeast Asian population descent 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Alpha Thalassemia Treatment market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Alpha Thalassemia Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug Type
- Folic Acid
- Deferasirox
- Deferiprone
- Hydroxyurea
Region Segment (2020-2030; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
- Pre COVID-19 situation
- Post COVID-19 situation
Key questions answered in this report:
- What are the key micro and macro environmental factors that are impacting the growth of Alpha Thalassemia Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Alpha Thalassemia Treatment market?
- Which is the largest regional market for Alpha Thalassemia Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Alpha Thalassemia Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Alpha Thalassemia Treatment market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Alpha Thalassemia Treatment Market
- 2.2. Global Alpha Thalassemia Treatment Market, By , 2021 (US$ Million)
- 2.3. Global Alpha Thalassemia Treatment Market, By Drug Type, 2021 (US$ Million)
- 2.4. Global Alpha Thalassemia Treatment Market, By Geography, 2021 (US$ Million)
- 2.5. Impact of Covid 19
- 2.6. Attractive Investment Proposition by Geography, 2021
- 2.7. Competitive Analysis
- 2.7.1. Market Positioning of Key Alpha Thalassemia Treatment Market Vendors
- 2.7.2. Strategies Adopted by Alpha Thalassemia Treatment Market Vendors
- 2.7.3. Key Industry Strategies
3. Alpha Thalassemia Treatment Market: Business Outlook & Market Dynamics
- 3.1. Introduction
- 3.2. Global Alpha Thalassemia Treatment Market Value, 2020 - 2030, (US$ Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers
- 3.3.2. Market Restraints
- 3.3.3. Key Challenges
- 3.3.4. Key Opportunities
- 3.4. Impact Analysis of Drivers and Restraints
- 3.5. See-Saw Analysis
- 3.6. Porter's Five Force Model
- 3.6.1. Supplier Power
- 3.6.2. Buyer Power
- 3.6.3. Threat Of Substitutes
- 3.6.4. Threat Of New Entrants
- 3.6.5. Competitive Rivalry
- 3.7. PESTEL Analysis
- 3.7.1. Political Landscape
- 3.7.2. Economic Landscape
- 3.7.3. Technology Landscape
- 3.7.4. Legal Landscape
- 3.7.5. Social Landscape
4. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
- 4.1. Market Overview
- 4.2. Growth & Revenue Analysis: 2021 Versus 2030
- 4.3. Market Segmentation
5. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Folic Acid
- 5.3.2. Deferasirox
- 5.3.3. Deferiprone
- 5.3.4. Hydroxyurea
6. North America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
- 6.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
- 6.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
- 6.4.1.North America
- 6.4.1.1. U.S.
- 6.4.1.2. Canada
- 6.4.1.3. Rest of North America
7. UK and European Union Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
- 7.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
- 7.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
- 7.4.1.UK and European Union
- 7.4.1.1. UK
- 7.4.1.2. Germany
- 7.4.1.3. Spain
- 7.4.1.4. Italy
- 7.4.1.5. France
- 7.4.1.6. Rest of Europe
8. Asia Pacific Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
- 8.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
- 8.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
- 8.4.1.Asia Pacific
- 8.4.1.1. China
- 8.4.1.2. Japan
- 8.4.1.3. India
- 8.4.1.4. Australia
- 8.4.1.5. South Korea
- 8.4.1.6. Rest of Asia Pacific
9. Latin America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
- 9.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
- 9.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Latin America
- 9.4.1.1. Brazil
- 9.4.1.2. Mexico
- 9.4.1.3. Rest of Latin America
10. Middle East and Africa Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
- 10.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
- 10.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Middle East and Africa
- 10.4.1.1. GCC
- 10.4.1.2. Africa
- 10.4.1.3. Rest of Middle East and Africa
11. Company Profile
- 11.1. GlaxoSmithKline Plc
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Portfolio
- 11.1.4. Strategic Initiatives
- 11.2. Bellicum Pharmaceuticals
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Portfolio
- 11.2.4. Strategic Initiatives
- 11.3. Novartis AG
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Portfolio
- 11.3.4. Strategic Initiatives
- 11.4. Acceleron Pharma
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Portfolio
- 11.4.4. Strategic Initiatives
- 11.5. Johnson & Johnson
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Portfolio
- 11.5.4. Strategic Initiatives
- 11.6. Merck & Co Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Portfolio
- 11.6.4. Strategic Initiatives
- 11.7. Alnylam Pharmaceuticals Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Portfolio
- 11.7.4. Strategic Initiatives
- 11.8. Calimmune Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Portfolio
- 11.8.4. Strategic Initiatives
- 11.9. Editas Medicine Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Portfolio
- 11.9.4. Strategic Initiatives
- 11.10. Gilead Sciences Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Portfolio
- 11.10.4. Strategic Initiatives